ArticleAnesthesia and analgesia2019
Pharmacological Characters of Oliceridine, a μ-Opioid Receptor G-Protein-Biased Ligand in Mice.
Article in Anesthesia and analgesia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review.Drug design, development and therapy · 2023Pooled it
- Oliceridine used for patient-controlled analgesia on postoperative quality of recovery in patients undergoing laparoscopic gynecological tumour resection: a randomized clinical trial.Annals of medicine · 2026Trial
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR8554, a biased µ-opioid receptor agonist: a phase I trial in healthy volunteers.BMC pharmacology & toxicology · 2026Trial
- A Comparison of Oliceridine versus Sufentanil for Patient-Controlled Analgesia After Total Knee Arthroplasty in Elderly Patients: A Double-Blinded Randomized Controlled Study.Drug design, development and therapy · 2026Trial
- Effect of Oliceridine on the Acute Postoperative Pain Management After Elective Cesarean Delivery: A Randomized Non-Inferiority Trial.Drug design, development and therapy · 2026Trial
- Comparison of Oliceridine and Hydromorphone for Postoperative Analgesia in Adults Undergoing Lower Limb Fracture Surgery: A Randomized Controlled Non-Inferiority Trial.Drug design, development and therapy · 2026Trial
- Comparison of Postoperative Analgesic Efficacy of Oliceridine and Sufentanil in Total Laparoscopy Hysterectomy, a Clinical Double-Blind Controlled Trial.Drug design, development and therapy · 2026Trial
- Effect of Oliceridine Fumarate for Patient-Controlled Intravenous Analgesia on Gastrointestinal Function in Laparoscopic Radical Gastrectomy Surgery: A Randomized, Double-Blind, Controlled Trial.Drug design, development and therapy · 2026Trial
- Protectin DX resolves fracture-induced postoperative pain in mice via neuronal signaling and GPR37-activated macrophage efferocytosis.The Journal of clinical investigation · 2026Article
- Article
- Arrestin-biased allosteric modulator of neurotensin receptor 1 alleviates acute and chronic pain.Cell · 2025Article
- Morphine-induced hyperalgesia impacts small extracellular vesicle microRNA composition and function.The Journal of pharmacology and experimental therapeutics · 2025Article
- Biased Opioid Receptor Agonists: Balancing Analgesic Efficacy and Side-Effect Profiles.International journal of molecular sciences · 2025Review
- Overview and Prospects of the Clinical Application of Oliceridine.Drug design, development and therapy · 2025Review
- Morphine-induced hyperalgesia impacts small extracellular vesicle miRNA composition and function.bioRxiv : the preprint server for biology · 2024Article
- Opioid system and related ligands: from the past to future perspectives.Journal of anesthesia, analgesia and critical care · 2024Review
- Global Trends in Oliceridine (TRV130) Research from 2013 to 2024: A Bibliometrics and Knowledge Graph Analysis.Drug design, development and therapy · 2024Article
- Targeting Opioid Receptors in Addiction and Drug Withdrawal: Where Are We Going?International journal of molecular sciences · 2023Review
- State and Future Science of Opioids and Potential of Biased-ligand Technology in the Management of Acute Pain After Burn Injury.Journal of burn care & research : official publication of the American Burn Association · 2023Review
- New sedatives and analgesic drugs for gastrointestinal endoscopic procedures.Clinical endoscopy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundA major advancement in the field of analgesic pharmacology has been the development of G-protein-biased opioid agonists that display less respiratory depression than conventional drugs. It is uncertain, however, whether these new drugs cause less tolerance, hyperalgesia, and other maladaptations when administered repeatedly.
methodsThe archetypical µ-opioid receptor agonist morphine and, separately, the G-protein-biased µ-opioid receptor agonist oliceridine were administered to mice. These drugs were used in models of acute analgesia, analgesic tolerance, opioid-induced hyperalgesia, reward, and physical dependence. In addition, morphine and oliceridine were administered for 7 days after tibia fracture and pinning; mechanical allodynia and gait were followed for 3 weeks. Finally, the expression of toll-like receptor-4 and nacht domain-, leucine-rich repeat-, and pyrin domain-containing protein 3 (NALP3) and interleukin-1β mRNA were quantified in spinal tissue to measure surgical and drug effects on glia-related gene expression.
resultsWe observed using the tail flick assay that oliceridine was a 4-fold more potent analgesic than morphine, but that oliceridine treatment caused less tolerance and opioid-induced hyperalgesia than morphine after 4 days of ascending-dose administration. Using similar analgesic doses, morphine caused reward behavior in the conditioned place preference assay while oliceridine did not. Physical dependence was, however, similar for the 2 drugs. Likewise, morphine appeared to more significantly impair the recovery of nociceptive sensitization and gait after tibial fracture and pinning than oliceridine. Furthermore, spinal cord toll-like receptor-4 levels 3 weeks after fracture were higher in fracture mice given morphine than those given oliceridine.
conclusionsAside from reduced respiratory depression, G-protein-biased agonists such as oliceridine may reduce opioid maladaptations and enhance the quality of surgical recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.